Upregulation of IGF-I and IGF-IR in HBV-HCC cell lines with inflamed-CM treatment.

mRNA levels of IGF-I and IGF-IR in human HCC cell lines of HepG2.2.15, Hep3B, PLC5 (HBV+HBsAg+), HA22T (HBV+HBsAg), HepG2, and Huh7 (HBVHBsAg) with inflamed-CM treatment for 7 days (by quantitative real-time RT-PCR). The dashed line indicates the gene expression in HCC cells without inflamed-CM treatment (multiple of expression = 1, control group). (B) IGF-IR levels in HCC cells with and without inflamed-CM treatment (by Western blotting). (C) Effect of inflamed-CM on the activation of IGF-IR/Akt signaling in HBV+HBsAg+ HepG2.2.15 and Hep3B is shown. (D) Effect of IGF-IR phosphorylation inhibitor PPP on inflamed-CM-induced IGF-IR/Akt signaling activation is shown. Effect of PPP (1 μM) on inflamed-CM-induced mRNA levels of OCT4 (E) and NANOG (F) in HepG2.2.15 and Hep3B cells is shown. **P < .01, ***P < .001, by t-test.